Charles Debattista
Professor of Psychiatry and Behavioral Sciences at Stanford University
Data updated
Research Footprint
Charles Debattista appears in 6 tracked papers (2018–2026), most studied alongside Ketamine, Placebo and Psilocybin, across Depressive Disorders, Suicidality and Treatment-Resistant Depression (TRD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Boris Heifets, Sanjay Mathew and Gerard Sanacora.
Background & Research
Charles DeBattista is a Stanford psychiatrist specializing in treatment-resistant depression, clinical psychopharmacology, and neuromodulation. He directs the Depression Research Clinic at Stanford and has published extensively on biological and pharmacologic treatments for mood disorders. His recent collaborative work includes studies of ketamine and psilocybin in depression and suicidal ideation.
Key Impact
He is a Stanford psychiatrist and depression researcher who appears on multiple ketamine and psilocybin clinical studies, making him a notable academic contributor to psychedelic psychiatry and rapid-acting antidepressant research.
Collaboration Network
37 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Charles Debattista is associated with.